4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-21-061973
Chief Scientific Officer sold 400 shares at $35.00 ($14,000)
- Chief Scientific Officer acquired 400 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hansen Gwenn Chief Scientific Officer | 2021-10-27 | Option exercise | +400 | $7.26 | $2,904 | 14,597 | D |
| Hansen Gwenn Chief Scientific Officer | 2021-10-27 | Sale | −400 | $35.00 | $14,000 | 14,197 | D |
| Derivatives | |||||||
| Hansen Gwenn Chief Scientific Officer | 2021-10-27 | Option exercise · Employee Stock Option (right to buy) | −400 | 68,666 | D | ||
| Open-market sales · 400 sh · avg $35.00 · $14,000 | |||||||
Loading xslF345X03/doc4.xml…